Qianjiang Yongan Pharmaceutical Co., Ltd.
Simbols: 002365.SZ
SHZ
8.24
CNYTirgus cena šodien
1753.8874
P/E koeficients
28.8139
PEG koeficients
2.43B
MRK Cap
- 0.01%
DIV ienesīgums
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3696.04 | 956.5 | 832.2 | 547.5 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 2581.9 | 630.4 | 557.5 | 454 | ||||||||||||||||||
balance-sheet.row.net-receivables | 794.98 | 178.4 | 203.1 | 367.8 | ||||||||||||||||||
balance-sheet.row.inventory | 310.95 | 69.9 | 149.6 | 145.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 21.25 | 8.8 | 10.4 | 4.8 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 4823.23 | 1213.6 | 1195.3 | 1065.9 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 3948.37 | 970.9 | 1023.5 | 989.3 | ||||||||||||||||||
balance-sheet.row.goodwill | 18.57 | 0.5 | 8.8 | 8.8 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 331.84 | 82.4 | 84.5 | 87.9 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 350.41 | 82.9 | 93.3 | 96.7 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -926.92 | 68.3 | -476.1 | -338.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 40.83 | 11.3 | 9.7 | 9.9 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 1311.93 | 0.1 | 578.5 | 462.9 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 4724.61 | 1133.5 | 1228.8 | 1220 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 9547.85 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 542.02 | 128.8 | 162.8 | 114.9 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 93.03 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.tax-payables | 56.99 | 7.8 | 4.9 | 5.5 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 35.42 | 8.5 | 11.3 | 13.1 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 114.65 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 161.86 | 65.6 | 70.6 | 78.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 141.57 | 33.1 | 36 | 35.6 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-liab | 1163.17 | 290.3 | 321.2 | 328.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 1178.73 | 294.7 | 294.7 | 294.7 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 3406.61 | 812.7 | 854.5 | 728.2 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2079.42 | 163.8 | 155.4 | 130.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1425.56 | 712.8 | 712.8 | 712.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 8090.32 | 1983.9 | 2017.4 | 1865.9 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 9547.85 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 285.85 | 64.4 | 85.6 | 91.1 | ||||||||||||||||||
balance-sheet.row.total-equity | 8376.17 | 2048.3 | 2103 | 1957 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 9547.85 | - | - | - | ||||||||||||||||||
Total Investments | 1654.98 | 698.7 | 81.4 | 115.2 | ||||||||||||||||||
balance-sheet.row.total-debt | 93.03 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.net-debt | -1021.1 | -278.9 | -234.7 | -73.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1.38 | -12.3 | 132.7 | 119 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.09 | 135.2 | 123.6 | 116 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 6.8 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -176.9 | 0.9 | 12.4 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 106.58 | 93.5 | 99.1 | -152.4 | ||||||||||||||||||
cash-flows.row.account-receivables | 18.85 | 18.9 | 163.2 | -172.1 | ||||||||||||||||||
cash-flows.row.inventory | 87.73 | 87.7 | -10 | -63.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -13.1 | -56.5 | 87.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 71.81 | 197.9 | 28.5 | 10.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 179.87 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -119.09 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0.87 | 1 | 0.4 | -35.9 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1350.13 | -1484.2 | -1110.7 | -823.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1299.19 | 1392.7 | 1029 | 943.5 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 22.57 | 45.2 | 0 | 0.5 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -123.95 | -166 | -230.4 | 21.8 | ||||||||||||||||||
cash-flows.row.debt-repayment | -10.6 | -30 | -40 | -132.3 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -44.62 | -29.5 | -1.6 | -30.7 | ||||||||||||||||||
cash-flows.row.other-financing-activites | -2.27 | -6.3 | 59.4 | 23.8 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -41.19 | -65.8 | 17.8 | -139.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 10.45 | 7.1 | 6.5 | -1.1 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 9.69 | 51.5 | 181.2 | -16.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1070.94 | 326.2 | 274.7 | 93.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1061.25 | 274.7 | 93.5 | 110.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 179.87 | 244.3 | 387.3 | 101.8 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -119.09 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 60.78 | 123.5 | 238.2 | 38.8 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 852.45 | 962.8 | 1462.4 | 1565.4 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 643.48 | 733.5 | 980.8 | 1206.9 | ||||||||||||||||||
income-statement-row.row.gross-profit | 208.97 | 229.3 | 481.7 | 358.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 41.02 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 73.14 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 18.03 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -94.9 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 280.6 | 205 | 320.3 | 228.6 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 924.08 | 938.5 | 1301.1 | 1435.4 | ||||||||||||||||||
income-statement-row.row.interest-income | 1.56 | 1.9 | 0.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.4 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 18.03 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 66.41 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -94.9 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 66.41 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.4 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 59.89 | 135.2 | 167.1 | 132.3 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -1.6 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -43.84 | 24.3 | 152.4 | 131.7 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 22.57 | 3.4 | 153.1 | 129.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 38.46 | 34.5 | 20.3 | 10.8 | ||||||||||||||||||
income-statement-row.row.net-income | 1.38 | -12.3 | 140.3 | 111.4 |
Biežāk uzdotie jautājumi
Kas ir Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) kopējie aktīvi?
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) kopējie aktīvi ir 2347138093.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 360799673.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.245.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.206.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.002.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -0.051.
Kāda ir Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -12312563.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 47305897.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 205002116.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 244645727.000.